GSK confirms Arexvy is a blockbuster but says the RSV battle has just begun

In the search results provided, GSK (GlaxoSmithKline) has confirmed that their launch of Arexvy, a major drug, has been exceptional, potentially implying that it has achieved "blockbuster" status within the industry. A blockbuster drug is typically one that earns over $1 billion in revenue annually. However, the specific details regarding Arexvy's financial performance are not directly stated in the provided search results.

The information about Arexvy's success is mentioned in conjunction with GSK's broader performance in 2023. Additionally, there is a reference to the company resolving a legal case related to a different product, which is not directly relevant to the performance of Arexvy.

The statement "the RSV battle has just begun" suggests that GSK is preparing for ongoing competition in the Respiratory Syncytial Virus (RSV) treatment market. It hints at the recognition that the successful launch of Arexvy is only one milestone in a broader, ongoing research and development effort to address RSV treatment needs.

As a biotechnology industry analyst, based on the search results, it can be concluded that GSK has confirmed the strong performance of Arexvy, which may qualify as a blockbuster drug, but the company also acknowledges the continuous challenge in the RSV market and their readiness to maintain a competitive advantage in this space.